VTYX
Ventyx Biosciences, Inc.
No data for this timeframe.
Vol
Inst. Holders8 funds
Inst. Value$88.9M
Inst. Activity3 buys / 1 sells
Reddit Sentiment60° Warm
SEC Reports2
Recent Activity
Mar 16, 2026
SEC
Ventyx Biosciences, Inc. (VTYX) has filed Form 15-12G to terminate the registration of its Common Stock under Section 12
15-12G — Impact 7/10
Mar 9, 2026
SEC
Ventyx Biosciences, Inc. has two Form EFFECT filings with effectiveness dates of March 6, 2026, indicating that two sepa
EFFECT — Impact 5/10
Mar 4, 2026
Insider
Forman Mark S sold 6,000 shares
Chief Medical Officer @ $0.00 ($0.00)
Mar 4, 2026
Insider
Forman Mark S sold 85,000 shares
Chief Medical Officer @ $0.00 ($0.00)
Mar 4, 2026
Insider
Nuss John sold 489,481 shares
CHIEF SCIENTIFIC OFFICER @ $0.00 ($0.00)
Inst.
MORGAN STANLEY — DOUBLED
4,292,951 shares ($38.8M)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
538,071 shares ($4.9M)
May 13, 2026
earnings_calendar
VTYX Q1 2026 Earnings Scheduled — 2026-05-13
Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$13.00 (Jan 2026)
Current $14.00
Low $9.00
Median $14.00
High $14.00
5 analysts
$9.00
$14.00
Analyst Ratings
2Strong Buy
4Buy
9Hold
0Sell
0Strong Sell
Historical Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jan 8, 2026 | Oppenheimer | DOWNGRADE | Outperform → Perform |
| Jan 8, 2026 | Wells Fargo | DOWNGRADE | Overweight → Equal-Weight |
| Jan 8, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy → Neutral |
| Jan 8, 2026 | UBS | DOWNGRADE | Buy → Neutral |
| Jan 8, 2026 | LifeSci Capital | DOWNGRADE | Outperform → Market Perform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Next Q | $-0.40 ▼ -3.9% | $-0.51 — $-0.28 | -1% YoY | 2 |
| Next FY | $-1.57 ▲ +3.9% | $-2.08 — $-1.23 | -6% YoY | 4 |
| Current Q | $-0.39 ▼ -8.8% | $-0.49 — $-0.29 | 4% YoY | 4 |
| Current FY | $-1.48 ▼ -2.4% | $-1.57 — $-1.37 | 25% YoY | 4 |
Latest Reports
BEARISH
15-12G
7/10
Ventyx Biosciences, Inc. (VTYX) has filed Form 15-12G to terminate the registration of its Common Stock under Section 12
Mar 16, 2026
NEUTRAL
EFFECT
5/10
Ventyx Biosciences, Inc. has two Form EFFECT filings with effectiveness dates of March 6, 2026, indicating that two sepa
Mar 9, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| MORGAN STANLEY | $38.8M | DOUBLED |
| VANGUARD GROUP INC | $35.6M | — |
| RENAISSANCE TECHNOLOGIES LLC | $4.9M | DOUBLED |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $3.5M | NEW |
| TWO SIGMA INVESTMENTS, LP | $3.3M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Mar 4, 2026 | Forman Mark | D | $0.00 |
| Mar 4, 2026 | Forman Mark | D | $0.00 |
| Mar 4, 2026 | Nuss John | D | $0.00 |
| Mar 4, 2026 | GUJRATHI SHEILA | D | $0.00 |
| Mar 4, 2026 | Subramaniam Somu | D | $0.00 |
Reddit Sentiment
60°
Warm
Bearish
Neutral
Bullish
8 institutional holders with $88.9M total value (9,847,127 shares) as of 2025-Q4. Top holders: MORGAN, VANGUARD, RENAISSANCE. Net buying activity: 3 institutions added/increased vs 1 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | MORGAN STANLEY | 4,292,951 | $38.8M | 43.6% | DOUBLED +1661.2% |
| 2 | VANGUARD GROUP INC | 3,943,566 | $35.6M | 40.0% | — |
| 3 | RENAISSANCE TECHNOLOGIES LLC | 538,071 | $4.9M | 5.5% | DOUBLED +129.0% |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 383,231 | $3.5M | 3.9% | NEW |
| 5 | TWO SIGMA INVESTMENTS, LP | 359,930 | $3.3M | 3.7% | NEW |
| 6 | BANK OF AMERICA CORP /DE/ | 316,856 | $2.9M | 3.2% | TRIM -40.1% |
| 7 | FMR LLC | 11,422 | $103.1K | 0.1% | TRIM -68.8% |
| 8 | WELLS FARGO & COMPANY/MN | 1,100 | $9.9K | 0.0% | DOUBLED +1000.0% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| MORGAN STANLEY | DOUBLED | 243,757 | 4,292,951 | +1661.2% | $38.8M | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 235,000 | 538,071 | +129.0% | $4.9M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 529,249 | 316,856 | -40.1% | $2.9M | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | DOUBLED | 100 | 1,100 | +1000.0% | $9.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 838,387 | 529,249 | -36.9% | $1.6M | 2025-Q3 |
| UBS Group AG | ADD | 367,509 | 527,292 | +43.5% | $1.6M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | NEW | — | 436,082 | — | $1.4M | 2025-Q3 |
| MORGAN STANLEY | TRIM | 521,018 | 243,757 | -53.2% | $758.1K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | 71,300 | 235,000 | +229.6% | $730.9K | 2025-Q3 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 628 | 100 | -84.1% | $311.00 | 2025-Q3 |
| MORGAN STANLEY | TRIM | 876,161 | 521,018 | -40.5% | $1.1M | 2025-Q2 |
| RENAISSANCE TECHNOLOGIES LLC | NEAR_EXIT | 1,016,389 | 71,300 | -93.0% | $152.6K | 2025-Q2 |
| FMR LLC | TRIM | 43,066 | 13,446 | -68.8% | $28.8K | 2025-Q2 |
| WELLS FARGO & COMPANY/MN | NEAR_EXIT | 36,978 | 628 | -98.3% | $1.3K | 2025-Q2 |
| CITADEL ADVISORS LLC | TRIM | 4,585,167 | 1,430,938 | -68.8% | $1.6M | 2025-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 624,500 | 1,016,389 | +62.8% | $1.2M | 2025-Q1 |
| MORGAN STANLEY | TRIM | 2,510,876 | 876,161 | -65.1% | $1.0M | 2025-Q1 |
| UBS Group AG | NEAR_EXIT | 3,782,583 | 309,612 | -91.8% | $356.1K | 2025-Q1 |
| TWO SIGMA INVESTMENTS, LP | EXIT | 476,291 | 0 | -100.0% | $0.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 1,197,386 | 3,782,583 | +215.9% | $8.3M | 2024-Q4 |
| MORGAN STANLEY | DOUBLED | 332,677 | 2,510,876 | +654.7% | $5.5M | 2024-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 313,700 | 624,500 | +99.1% | $1.4M | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 485,101 | — | $1.1M | 2024-Q3 |
| MORGAN STANLEY | TRIM | 630,777 | 332,677 | -47.3% | $725.2K | 2024-Q3 |
10 unique insiders with 0 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | Forman Mark S | Chief Medical Officer | D | 6,000 | $0.00 | $0.00 |
| Mar 4, 2026 | Forman Mark S | Chief Medical Officer | D | 85,000 | $0.00 | $0.00 |
| Mar 4, 2026 | Nuss John | CHIEF SCIENTIFIC OFFICER | D | 489,481 | $0.00 | $0.00 |
| Mar 4, 2026 | GUJRATHI SHEILA | Director | D | 33,000 | $0.00 | $0.00 |
| Mar 4, 2026 | Subramaniam Somu | Director | D | 33,000 | $0.00 | $0.00 |
| Mar 4, 2026 | GUJRATHI SHEILA | Director | D | 130,000 | $0.00 | $0.00 |
| Mar 4, 2026 | Subramaniam Somu | Director | D | 3,337,495 | $0.00 | $0.00 |
| Mar 4, 2026 | White William Richard | Director | D | 33,000 | $0.00 | $0.00 |
| Mar 4, 2026 | Moore Matthew Richard | Chief Operating Officer | D | 145,000 | $0.00 | $0.00 |
| Mar 4, 2026 | HULME ALLISON | Director | D | 33,000 | $0.00 | $0.00 |
| Mar 4, 2026 | Cadoret-Manier Onaiza | Director | D | 33,000 | $0.00 | $0.00 |
| Mar 4, 2026 | Gonzales Roy | Senior VP, Finance | D | 5,313 | $0.00 | $0.00 |
| Mar 4, 2026 | Gonzales Roy | Senior VP, Finance | D | 109,200 | $0.00 | $0.00 |
| Mar 4, 2026 | Mohan Raju | CEO AND PRESIDENT | D | 2,372,863 | $0.00 | $0.00 |
| Mar 4, 2026 | Mohan Raju | CEO AND PRESIDENT | D | 23,688 | $0.00 | $0.00 |
| Mar 4, 2026 | Mohan Raju | CEO AND PRESIDENT | D | 700,000 | $0.00 | $0.00 |
| Mar 4, 2026 | Nuss John | CHIEF SCIENTIFIC OFFICER | D | 9,063 | $0.00 | $0.00 |
| Mar 4, 2026 | Nuss John | CHIEF SCIENTIFIC OFFICER | D | 415,104 | $0.00 | $0.00 |
| Feb 27, 2026 | Subramaniam Somu | Director | J | 694,718 | $0.00 | $0.00 |
2 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 1 neutral. Avg impact: 6.0/10.
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Historical analyst distribution (last covering-analyst action Jan 2026): 40% buy across 15 analysts — 2 strong buy, 4 buy, 9 hold, 0 sell, 0 strong sell. No current recommendation available.
Analyst Price Targets
Historical data — last covering-analyst action Jan 2026. No current recommendation available.
$13.00 mean target (Jan 2026)
$9.00 Low
$14.00 High
| Metric | Value |
|---|---|
| Current Price | $14.00 |
| Target Low | $9.00 |
| Target Mean | $13.00 |
| Target Median | $14.00 |
| Target High | $14.00 |
| # Analysts | 5 |
| Recommendation | — (no recent coverage) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Next Q 2026-03-31 |
$-0.40 | $-0.51 | $-0.28 | -1.3% | -3.9% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2026-12-31 |
$-1.57 | $-2.08 | $-1.23 | -5.9% | +3.9% | 1↑ 1↓ | $0.0B | 0.0% | 4 |
| Current Q 2025-12-31 |
$-0.39 | $-0.49 | $-0.29 | 3.8% | -8.8% | 1↑ 0↓ | $0.0B | 0.0% | 4 |
| Current FY 2025-12-31 |
$-1.48 | $-1.57 | $-1.37 | 25.0% | -2.4% | 2↑ 0↓ | $0.0B | 0.0% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.394 | |
| 7d ago | $-0.363 | -0.032 |
| 30d ago | $-0.363 | -0.032 |
| 60d ago | $-0.364 | -0.030 |
| 90d ago | $-0.364 | -0.030 |
12 analyst firms have rated this stock: 3 upgrades, 10 downgrades, 5 initiations.
Historical Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jan 8, 2026 | Oppenheimer | DOWNGRADE | Outperform | Perform |
| Jan 8, 2026 | Wells Fargo | DOWNGRADE | Overweight | Equal-Weight |
| Jan 8, 2026 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Jan 8, 2026 | UBS | DOWNGRADE | Buy | Neutral |
| Jan 8, 2026 | LifeSci Capital | DOWNGRADE | Outperform | Market Perform |
| Jan 8, 2026 | Canaccord Genuity | DOWNGRADE | Buy | Hold |
| Jan 7, 2026 | UBS | INITIATE | — | Buy |
| Nov 7, 2025 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Nov 7, 2025 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Nov 5, 2025 | HC Wainwright & Co. | UPGRADE | Neutral | Buy |
| Oct 27, 2025 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Oct 1, 2025 | Clear Street | INITIATE | — | Buy |
| Jan 14, 2025 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Nov 11, 2024 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Nov 8, 2024 | Oppenheimer | REITERATE | Outperform | Outperform |
| Oct 15, 2024 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Sep 23, 2024 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Aug 12, 2024 | Wells Fargo | MAINTAIN | Overweight | Overweight |
| Aug 12, 2024 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Jul 30, 2024 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Jun 13, 2024 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Jun 6, 2024 | Oppenheimer | MAINTAIN | Outperform | Outperform |
| Jun 6, 2024 | HC Wainwright & Co. | REITERATE | Neutral | Neutral |
| Mar 13, 2024 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Mar 12, 2024 | Wells Fargo | UPGRADE | Equal-Weight | Overweight |
| Mar 12, 2024 | Oppenheimer | UPGRADE | Perform | Outperform |
| Mar 11, 2024 | Canaccord Genuity | MAINTAIN | Buy | Buy |
| Feb 21, 2024 | Oppenheimer | REITERATE | — | Perform |
| Dec 19, 2023 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Dec 18, 2023 | Stifel | MAINTAIN | Hold | Hold |
| Nov 10, 2023 | Evercore ISI Group | DOWNGRADE | Outperform | In-Line |
| Nov 7, 2023 | Morgan Stanley | DOWNGRADE | Overweight | Equal-Weight |
| Nov 7, 2023 | Stifel | DOWNGRADE | Buy | Hold |
| Nov 7, 2023 | HC Wainwright & Co. | DOWNGRADE | Buy | Neutral |
| Oct 10, 2023 | Stifel | REITERATE | Buy | Buy |
| Oct 10, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Aug 29, 2023 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Aug 11, 2023 | Credit Suisse | MAINTAIN | Outperform | Outperform |
| Aug 11, 2023 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Jul 5, 2023 | Oppenheimer | REITERATE | Outperform | Outperform |
| Jul 5, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| May 12, 2023 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 24, 2023 | Credit Suisse | REITERATE | — | Outperform |
| Mar 24, 2023 | Oppenheimer | MAINTAIN | — | Outperform |
| Mar 21, 2023 | Wells Fargo | INITIATE | — | Overweight |
| Mar 20, 2023 | HC Wainwright & Co. | REITERATE | — | Buy |
| Jan 31, 2023 | Canaccord Genuity | MAINTAIN | — | Buy |
| Jan 27, 2023 | Oppenheimer | MAINTAIN | — | Outperform |
| Dec 19, 2022 | Goldman Sachs | INITIATE | — | Buy |
| Nov 17, 2022 | Morgan Stanley | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| May 1, 2026 | 2 | 4 | 9 | 0 | 0 | 40% | |
| Apr 1, 2026 | 2 | 4 | 9 | 0 | 0 | 40% | |
| Mar 1, 2026 | 2 | 4 | 9 | 0 | 0 | 40% | |
| Feb 1, 2026 | 2 | 4 | 9 | 0 | 0 | 40% | |
| Jan 1, 2026 | 4 | 9 | 2 | 0 | 0 | 87% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
60°
Warm
Bearish
Neutral
Bullish
1 mentions
1 bullish
0 bearish
1 time period
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Feb 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
$COCH is the future of implants and hearing
▲ 2
💬 9
⚡ 0.0
May 13, 2026
earnings_calendar
VTYX Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
VTYX Q1 2026 Earnings Scheduled — 2026-05-11
May 1, 2026
earnings_calendar
VTYX Q1 2026 Earnings Scheduled — 2026-05-01
Mar 19, 2026
earnings_calendar
VTYX Q4 2025 Earnings After Market Close — 2026-03-19
Feb 18, 2026
short_interest
FTD: VTYX — 52,570 shares ($0.7M) failed to deliver
Settlement: 20260218, Price: $13.95, FTD Value: $733,351.5, VENTYX BIOSCIENCES INC
Feb 17, 2026
short_interest
FTD: VTYX — 52,570 shares ($0.7M) failed to deliver
Settlement: 20260217, Price: $13.97, FTD Value: $734,402.9, VENTYX BIOSCIENCES INC
Feb 13, 2026
short_interest
FTD: VTYX — 154,381 shares ($2.2M) failed to deliver
Settlement: 20260213, Price: $13.93, FTD Value: $2,150,527.33, VENTYX BIOSCIENCES INC